Review of NICE Technology Appraisal Guidance Nos 103, 134 and 146 on the use of etanercept and efalizumab for the treatment of adults with psoriasis, infliximab for the treatment of psoriasis andadalimumab for the treatment of psoriasis

Review decision

The Institute was proposing that the decision to review the original guidance be deferred until 2010 when the evidence base would be assessed again to ascertain the need for a review of the guidance.

During consultation it was highlighted to us that the proposal might not be the best way to proceed with the review. After consideration of all the comments from consultation, the Institute's Guidance Executive has decided to recommend that the reviews of all the guidance should be combined and updated as a multiple technology appraisal. This appraisal should be planned into the work programme as soon as possible. We hope to begin working on this appraisal early next year depending on available resources.

• Summary of the responses from this consultation

31 December 2008